Related Experiment Videos
CDKN2 (MTS1/p16INK4A) gene alterations in adult T-cell leukemia/lymphoma
T Uchida1, T Kinoshita, T Murate
1First Department of Internal Medicine, Nagoya University School of Medicine, Japan.
Abstract:
p16INK4A is a cyclin-dependent kinase inhibitor (CDKI), and regulates the cell cycle negatively. Recently, p16INK4A protein was shown to be encoded by the CDKN2 gene, which is identical to multiple tumor suppressor gene 1 (MTS1) on chromosome 9p21, where genetic alterations occur frequently in many malignant tumors. As the loss of p16INK4A function by genetic alterations leads to inappropriate progression of the cell cycle, the CDKN2 gene has been investigated intensively as a new candidate tumor suppressor gene in many malignant tumors. Adult T-cell leukemia/lymphoma (ATLL) is a peripheral T-cell malignancy associated with human T-cell lymphotrophic virus type 1 (HTLV-1). As the development to ATL is believed to require not only HTLV-1 infection but also accumulation of genetic alterations, we investigated the relationship between alterations in the CDKN2 gene and ATL. Alterations in the CDKN2 gene were detected in approximately 15 to 20% of ATL patients. Interestingly, most of the patients with CDKN2 gene alterations had the aggressive form of ATL. The CDKN2 gene appears to be the major tumor suppressor gene on chromosome 9p21, and alteration in this gene may play an important role during late stages in the transformation process induced by HTLV-1.
Insights
Alterations in the CDKN2 gene, which encodes p16INK4A, were found in 15-20% of Adult T-cell leukemia/lymphoma (ATLL) patients. These CDKN2 gene alterations are linked to the aggressive form of ATLL, suggesting a role in disease progression.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- p16INK4A, a cell cycle regulator, is encoded by the CDKN2 gene, a known tumor suppressor locus on chromosome 9p21.
- Genetic alterations at 9p21 are common in various malignancies.
- Adult T-cell leukemia/lymphoma (ATLL) is a T-cell malignancy associated with HTLV-1, requiring multiple genetic alterations for development.
Purpose of the Study:
- To investigate the frequency and significance of CDKN2 gene alterations in ATLL.
- To determine the role of CDKN2 gene alterations in the pathogenesis of ATLL.
Main Methods:
- Analysis of CDKN2 gene alterations in a cohort of ATLL patients.
- Correlation of genetic alterations with clinical presentation and disease aggressiveness.
Main Results:
- CDKN2 gene alterations were detected in 15-20% of ATLL patients.
- A significant association was observed between CDKN2 gene alterations and the aggressive form of ATLL.
Conclusions:
- The CDKN2 gene is frequently altered in ATLL, particularly in aggressive cases.
- Alterations in the CDKN2 gene may contribute to the late stages of HTLV-1-induced T-cell transformation and ATLL development.